Progressive Keratoconus Clinical Trial
Official title:
Multicenter, Randomized Study Evaluating the Use of a Non-sutured Sterile Freeze-dried Amniotic Membrane Post Crosslinking in Subjects With Progressive Keratoconus
Crosslinking is a therapeutic technique used to increase the rigidity of the cornea in order to slow or stop progression of keratoconus. The main complication of the treatment of keratoconus by crosslinking is postoperative pain due to the removal of the corneal epithelium. Currently, the management of pain is done through the administration of artificial tears and paracetamol. The amniotic membrane is a biological tissue used in ophthalmology to treat injuries of the surface of the eye. It has healing and analgesic properties. The objective of this multicenter randomized study is to evaluate the benefit of placing an amniotic membrane on the eye post-crosslinking to reduce pain and promote corneal healing.
Status | Not yet recruiting |
Enrollment | 116 |
Est. completion date | September 2025 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Man or woman between 18 and 65 years old. - Indication for accelerated conventional crosslinking. - Patient with progressive keratoconus (increase in Kmax of = 0.5 diopters in 3 to 6 months or = 1 diopter in 3 to 12 months with loss of 10 microns on minimum pachymetry in 3 to 12 month). - Patient suffering from keratoconus with a compatible topographic form (Kmax = 47.0 diopters (D) and difference inferior-superior of 1.5 D). - Patient with a minimum corneal thickness greater than 400 microns. - Informed and consenting patient. - Patient physically and mentally capable of completing the post-operative pain assessment self-questionnaire. - Patient having signed the informed consent of the French Ophthalmology Society for crosslinking. - Patient affiliated to a social security system or beneficiary of such a system. Exclusion Criteria: - Woman without effective means of contraception, pregnant or breastfeeding. - Patient who has already benefited from a crosslinking procedure on one of the eyes. - Patient with a history of refractive surgery on one of the eyes. - Patient with an intracorneal ring segment on one of the eyes. - Patient suffering from a serious systemic pathology (autoimmune and/or immunodepressive) - Patient with a psychiatric pathology. - Patient on long-term analgesics and/or corticosteroids. - Indication of crosslinking outside the classic protocol. - Patient with central corneal opacity. - Patient suffering from a severe dry eye syndrome or a neurotrophic keratitis. - Patient with a history of ocular herpes. - Patient with a history of ocular varicella-zoster virus infection. - Patient with glaucoma. - Patient treated with topical cyclosporine in the last 6 months. - Patient deprived of liberty by a judicial or administrative decision. - Patient subject to a legal protection measure or unable to express their consent. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
TBF Genie Tissulaire |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Difference between the level of ocular pain experienced by patients treated with therapeutic lens + amniotic membrane (experimental) and by patients treated with therapeutic lens alone (active comparator) | Pain evaluated from 0: no pain to 10: worst imaginable pain on visual analog scale (VAS) | Day 0 bedtime, Day 1 wake-up, Day 1 bedtime, Day 2 wake-up, Day 2 consultation | |
Primary | Difference in analgesic consumption between patients treated with a therapeutic lens + amniotic membrane (experimental) and patients treated with a therapeutic lens alone (active comparator) | Amount in grams of analgesic consumed per day | Day 0, Day 1, Day 2 | |
Secondary | Difference in visual acuity between eyes treated with therapeutic lens + amniotic membrane (experimental) and eyes treated with therapeutic lens alone (active comparator) | Determination of logMAR values of best corrected visual acuity | Week 6 | |
Secondary | Difference in corneal cicatrisation between eyes treated with therapeutic lens + amniotic membrane (experimental) and eyes treated with therapeutic lens alone (active comparator) | Healing evaluated under slit lamp by fluorescein examination | Day 2, (Day 7), Week 6 | |
Secondary | Difference in corneal thickness between eyes treated with therapeutic lens + amniotic membrane (experimental) and eyes treated with therapeutic lens alone (active comparator) | Corneal thickness evaluated by anterior segment optical coherence tomography. | Week 6 | |
Secondary | Difference in topographic parameters (Kmax, inferior-superior) between eyes treated with therapeutic lens + amniotic membrane (experimental) and eyes treated with therapeutic lens alone (active comparator) | Topographic parameters (Kmax, inferior-superior) evaluated by corneal topography | Week 6 | |
Secondary | Difference in dryness between eyes treated with therapeutic lens + amniotic membrane (experimental) and eyes treated with therapeutic lens alone (active comparator) | Dry eye and effect on vision evaluated between 0 (no disability) and 100 (greater disability) using Ocular Surface Disease Index (OSDI) | Week 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02721628 -
Epi-keratoplasty Versus Collagen Cross-Linking in Progressive Keratoconus
|
N/A | |
Completed |
NCT02883868 -
Stromal Demarcation Line: is it Predictive for Cross-Linking Efficiency?
|
N/A | |
Active, not recruiting |
NCT04427956 -
Corneal Crosslinking Treatment Study
|
Phase 4 | |
Terminated |
NCT01868620 -
Non-inferiority Trial of Iontophoretic Corneal Collagen Crosslinking (CXL) Compared to Standard Corneal Collagen Crosslinking in Progressive Keratoconus.
|
N/A | |
Recruiting |
NCT05314738 -
Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus
|
Phase 1/Phase 2 | |
Completed |
NCT02117999 -
Transepithelial Corneal Cross-linking Using Iontophoresis
|
N/A | |
Completed |
NCT01485211 -
Corneal Thickness Changes During Corneal Collagen Cross-linking With Ultraviolet-A Irradiation and Riboflavin
|
Phase 4 | |
Completed |
NCT04504578 -
Efficacy and Safety ofCACXL in the Treatment of Keratoconus With Thin Corneas
|
N/A | |
Completed |
NCT00567671 -
Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia
|
Phase 2/Phase 3 | |
Completed |
NCT00647699 -
Corneal Collagen Cross-linking for Progressive Keratoconus
|
Phase 3 | |
Recruiting |
NCT00815256 -
Safety and Effectiveness of Collagen Cross Linking in Progressive Mild and Moderate Keratoconus
|
Phase 3 | |
Recruiting |
NCT04045626 -
Study of Demarcation Line Depth in Transepithelial Versus Epithelium-off Accelerated Cross-linking (AXL) in Keratocouns
|
N/A | |
Completed |
NCT03442751 -
Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus
|
Phase 3 | |
Completed |
NCT01411384 -
Evaluation of Corneal Hysteresis and Corneal Resistance Factor After Corneal Cross-linking for Keratoconus
|
N/A | |
Withdrawn |
NCT00679666 -
Corneal Crosslinking in Keratoconus and Corneal Ectasia
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT00925327 -
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking for Compassionate Treatment in Pediatric Patients With Progressive Keratoconus
|
Phase 2 |